“Our team has made nothing short of transformational advancements throughout 2024. Fundamentally, the Company has never been stronger, and we believe we are poised to unlock value for all stakeholders in the near term,” commented John Climaco, Chief Executive Officer of CNS Pharmaceuticals (CNSP). “We have a strong cash position, expanded our pipeline in complete alignment with our mission and importantly, believe we are closer than ever to potentially bringing Berubicin, our targeted chemotherapy drug candidate, to market as a meaningful treatment option to GBM patients and practitioners.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CNSP:
- CNS Pharmaceuticals: Financial Results and Strategic Moves
- CNS Pharmaceuticals granted exception by Nasdaq to regain compliance
- Biotech Alert: Searches spiking for these stocks today
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
